Shares of NeurAxis, Inc. (NRXS) have gained 4.6% since the company reported results for the quarter ended Dec. 31, 2025, against a 0.8% decline in the S&P 500 over the same period. Over the past month, the stock has rallied sharply, gaining 38.5% against the S&P 500’s 5.1% decline.NeurAxis’ Earnings SnapshotNeurAxis reported fourth-quarter 2025 revenues of $968,000, up 27% year over year from $761,000, marking its sixth consecutive quarter of double-digit growth. The revenue increase was driven by a 35% ris ...

NeurAxis (NYSEAM:NRXS) Q4 2025 Earnings call March 19, 2026 09:00 AM ET Company ParticipantsBen Shamsian - VP of Investor RelationsBrian Carrico - President and CEOKaren Sterling - Managing DirectorTimothy Henrichs - CFOConference Call ParticipantsChase Knickerbocker - AnalystNone - AnalystOperatorLadies and gentlemen, thank you for standing by. Welcome to the NeurAxis Report, fourth quarter 2025 financial results. At this time, all participants are in a listen-only mode. After the speaker's presentation, t ...

NeurAxis (NYSEAM:NRXS) Q4 2025 Earnings call March 19, 2026 09:00 AM ET Company ParticipantsBen Shamsian - VP of Investor RelationsBrian Carrico - President and CEOKaren Sterling - Managing DirectorTimothy Henrichs - CFOConference Call ParticipantsChase Knickerbocker - AnalystNone - AnalystOperatorLadies and gentlemen, thank you for standing by. Welcome to the NeurAxis Report, Q4 2025 financial results. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be ...

NeurAxis (NYSEAM:NRXS) Q4 2025 Earnings call March 19, 2026 09:00 AM ET Speaker5Ladies and gentlemen, thank you for standing by. Welcome to the NeurAxis Report, fourth quarter 2025 financial results. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you would need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw ...

Core Insights - NeurAxis, Inc. has reported significant growth in revenues and operational milestones, indicating a new phase in its growth trajectory with the implementation of a Category I CPT code for its IB-Stim technology [3][6]. Financial Highlights - Revenues for Q4 2025 reached $968 thousand, a 27% increase from $761 thousand in Q4 2024, driven by a 35% increase in unit sales [5][6]. - For FY2025, revenues increased by 33% to $3.6 million compared to $2.7 million in FY2024, with unit sales up approximately 44% [7]. - The gross margin for Q4 2025 was 85.4%, down from 86.4% in Q4 2024, while the FY2025 gross margin was 84.2%, a decline from 86.5% in FY2024 [8]. Operational Highlights - The company has successfully transitioned to a Category I CPT code for its IB-Stim technology, enhancing market understanding and adoption potential [3][6]. - NeurAxis has secured a Veterans Affairs Federal Supply Schedule contract, facilitating access to the Veterans Affairs health system, which serves nearly 7 million patients annually [5]. - The company received FDA clearance for treating abdominal pain in functional dyspepsia for patients aged 8 and older, expanding the addressable market for IB-Stim [5]. Management Commentary - The CEO emphasized the importance of expanding medical policy coverage to increase patient access and reduce provider friction, alongside efforts to streamline reimbursement processes [4][6]. - The focus for early 2026 is on executing the commercial strategy and leveraging insights from real-world utilization to drive adoption [5][6]. Expense Overview - Selling, general, and administrative expenses for Q4 2025 were $2.5 million, a 20% increase from $2.1 million in Q4 2024, attributed to higher commissions and stock compensation costs [9]. - For FY2025, these expenses totaled $10.8 million, a 14% increase from $9.5 million in FY2024, influenced by a one-time legal settlement and increased marketing costs [10]. Loss Metrics - The operating loss for Q4 2025 was $1.7 million, up 17% from $1.5 million in Q4 2024, while the FY2025 operating loss was $7.8 million, a 9% increase from $7.2 million in FY2024 [11][12]. - The net loss for Q4 2025 was $1.7 million, an 18% increase from $1.4 million in Q4 2024, and the net loss for FY2025 was $7.8 million, a decrease of 5% from $8.2 million in FY2024 [11][12]. Cash Position - As of December 31, 2025, the company had a cash balance of $5.0 million, with short-term and long-term debt of $148 thousand and $10 thousand, respectively [13]. - Cash used in operations for FY2025 was $6.4 million, reflecting a $335 thousand increase from FY2024, primarily due to higher inventory purchases and incentive program payments [13].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission File Number: 001-41775 | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Common ...

Core Viewpoint - NeurAxis, Inc. is set to report its financial results for the fourth quarter and fiscal year 2025 on March 19, 2026, before market open, with a conference call scheduled for the same day to discuss the results [1]. Company Overview - NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies aimed at addressing chronic and debilitating conditions in both children and adults [4]. - The company is advancing its proprietary technology, IB-Stim®, which is a Percutaneous Electrical Nerve Field Stimulation (PENFS) device, FDA cleared for treating functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD), and related nausea symptoms in patients aged 8 and older [4]. - NeurAxis is conducting additional clinical trials of PENFS for various pediatric and adult conditions that have significant unmet healthcare needs [4]. Conference Call Details - The conference call will take place on March 19, 2026, at 9:00 am ET, and will be accessible via a live webcast [2]. - Participants can submit questions through the webcast portal or via email [2]. - Call-in participants must register to receive dial-in information and a unique PIN [3]. Additional Information - A replay of the conference call will be available on the company's Investor Relations website [3]. - For further inquiries, investors can contact Lytham Partners [6].

NeurAxis (NYSEAM:NRXS) FY Conference Summary Company Overview - **Company Name**: NeurAxis - **Ticker**: NRXS - **Industry**: Med Tech, specifically focused on neuromodulation therapies for gastrointestinal (GI) disorders - **Market Position**: Growth stage company with over 10 years of experience, recently expanded from pediatric to adult indications [2][3] Key Points and Arguments Corporate Developments - NeurAxis has secured a **Category I CPT code** for its PENFS technology effective January 1, 2026, which is crucial for scaling the technology and obtaining insurance coverage [3][4][21] - The company has expanded its **commercial payer coverage** to over **100 million covered lives**, enhancing access to its treatments [4][24] - In 2025, NeurAxis reported revenues exceeding **$3 million** with a gross margin of approximately **84%** [4][20] Market Opportunity - The **serviceable available market** for NeurAxis is estimated at **$22 billion** in the U.S., with specific indications like functional abdominal pain and IBS representing a **$3 billion market opportunity** [8][9] - There are about **6 million patients** in the U.S. with functional abdominal pain and IBS, with **10%** classified as debilitated [9] Clinical Focus - NeurAxis is concentrating on **functional abdominal pain** and **functional dyspepsia** in both pediatric and adult populations, with ongoing clinical trials for multiple indications [5][6] - The company emphasizes the importance of strong clinical data to support insurance coverage and reimbursement, which is critical for revenue growth [6][10] Competitive Advantage - NeurAxis is the only FDA-approved treatment recommended in pediatric guidelines for gut-brain interaction disorders, providing a unique market position [7][10] - The company has conducted **16 publications** of investigator-initiated research, demonstrating the efficacy and safety of its technology [12] Financial Outlook - NeurAxis has a clear path to profitability, with expectations for gross margins to approach **90%** in the coming year [29] - The company had **$5 million** in cash at the end of the previous quarter, with a monthly burn rate of approximately **$450,000-$500,000** [29][30] Challenges and Strategies - The company faces challenges in scaling due to previous lack of insurance coverage and the need for more trained providers to utilize the technology [17][22] - NeurAxis is actively working to increase insurance policy coverage and improve its market presence through strategic partnerships and data presentation [26][27] Additional Important Information - The management team is experienced, with 90% of the team having been involved in the company's growth [8] - The company is focused on maintaining a strong intellectual property portfolio, which is expected to last until **2039** [18] - NeurAxis is committed to transitioning its technology to frontline treatment options for patients, aiming for earlier intervention and better long-term outcomes [27][28]

Core Insights - NeurAxis, Inc. has achieved a significant milestone with the implementation of a Category I CPT code for its Percutaneous Electrical Nerve Field Stimulation (PENFS) therapy, which is expected to enhance commercial clarity and patient access to care [1][2][3] Group 1: CPT Code Significance - The assignment of the Category I CPT code is a breakthrough for the widespread adoption of NeurAxis' IB-Stim® therapy, establishing a recognized coding and billing pathway [2][8] - This coding reflects broad clinical acceptance and meets the American Medical Association's criteria for clinical efficacy and standards of care [2] Group 2: Business Impact - The implementation of the CPT code is anticipated to strengthen NeurAxis' business foundation by improving payer alignment and scalability across health systems [3] - The company believes that this will accelerate patient access to care, support coverage expansion, and drive long-term revenue growth [3] Group 3: Company Overview - NeurAxis focuses on neuromodulation therapies for chronic conditions in both children and adults, with its IB-Stim® technology FDA cleared for specific gastrointestinal issues in patients aged 8 and older [5] - The company is conducting additional clinical trials for PENFS in various pediatric and adult conditions with significant unmet healthcare needs [5]

Core Insights - The Zacks Equity Research team has highlighted several stocks, including Meta Platforms, Bank of America, Procter & Gamble, Espey Mfg. & Electronics, and NeurAxis, in their recent analysis [1][2] Meta Platforms, Inc. (META) - Meta's shares have outperformed the Zacks Internet - Software industry over the past year, with a gain of +3.6% compared to the industry's +1.1% [4] - The company is experiencing steady user growth, particularly in the Asia Pacific region, driven by increased engagement across its platforms like Instagram, WhatsApp, Messenger, and Facebook [4] - Meta is leveraging AI to enhance its platform offerings, reaching over 3.54 billion users daily, which is expected to drive top-line growth [5] - The company plans to invest significantly in developing advanced AI models, although monetization of these services may take time [6] Bank of America Corp. (BAC) - Bank of America's shares have increased by +16.2% over the past six months, slightly underperforming the Zacks Financial - Investment Bank industry's gain of +17.3% [7] - The company's net interest income (NII) is projected to grow at a CAGR of 5.7% by 2027, supported by decent loan growth despite rate cuts [7] - Total revenues are expected to grow by 6.9% in 2025, although trading revenue growth may normalize after a robust performance since 2022 [8] - Elevated expenses due to ongoing investments and weak asset quality may hinder bottom-line growth, with expenses expected to rise by 4.3% in 2025 [9] The Procter & Gamble Co. (PG) - Procter & Gamble's shares have declined by -10.4% over the past six months, slightly better than the Zacks Consumer Products - Staples industry's decline of -11% [10] - The company anticipates all-in sales growth of 1–5% and organic sales gains of flat to up 4% in fiscal 2026, supported by cost savings [11] - Robust cash flow is expected to fund $15 billion in shareholder returns in fiscal 2026, including dividends and share buybacks [11] - However, elevated commodity costs and macroeconomic challenges continue to pressure margins and earnings visibility [12] Espey Mfg. & Electronics Corp. (ESP) - Espey Mfg. & Electronics has outperformed the Zacks Electronics - Military industry over the past six months, with a gain of +3.5% compared to the industry's decline of -32.4% [13] - The company has a backlog of $141.1 million, with 72% scheduled through 2028+, ensuring revenue visibility despite a 12.9% sales decline in Q1 FY26 [13] - Gross margin has expanded to 35.4%, indicating strong cost control and product mix advantages [14] NeurAxis, Inc. (NRXS) - NeurAxis has outperformed the Zacks Medical Info Systems industry over the past six months, with a gain of +65.2% compared to the industry's decline of -16.2% [16] - The company targets a large market for gut/brain disorders with its FDA-cleared IB-Stim neuromodulation system, recently expanding its addressable market to $8 billion [16] - Revenue has been growing at double-digit rates, but the company continues to face losses due to high spending and margin pressure [17]